Through our venture philanthropy model, we provide early stage funding to companies to develop breakthrough drugs for adults and children with cystic fibrosis.
Learn about our focus for 2020-2024 as we advance our path to a cure, meet emerging challenges in care, and explore new ways to partner with and support the CF community.
Engaging with biotechnology and pharmaceutical companies is essential to reaching our goal of a cure for all people with cystic fibrosis. These principles and standards for Industry interactions safeguard our independence, objectivity, and ability to make decisions that are in the best interest of people with CF.
Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure.
The top 10 most-read blog posts of 2016 cover a range of topics and demonstrate the diversity of the cystic fibrosis community.
As I join the Foundation as chief operating officer, I look forward to taking the time to hear as many community voices as I can, to learn from all you have done and to engage to help do my part.